Free Trial
→ This document could hand you a shot at $915 every single weekend! (From WealthPress) (Ad) Buy ASTH Stock  Free ASTH Stock Alerts

Astrana Health (ASTH) Financials

Astrana Health logo
$24.61 -0.36 (-1.44%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$25.22 +0.61 (+2.48%)
As of 07:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Astrana Health

Annual Income Statements for Astrana Health

This table shows Astrana Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 3/31/2015 1/31/2014
Net Income / (Loss) Attributable to Common Shareholders		 43 61 45 69 38 14 11 26 11 -1.80 -4.56
Consolidated Net Income / (Loss)		 50 58 46 46 122 18 60 46 10 -1.35 -4.56
Net Income / (Loss) Continuing Operations		 50 58 46 46 122 18 60 46 10 -1.35 -4.56
Total Pre-Tax Income 		81 90 87 78 178 26 83 50 19 -1.18 -4.54
Total Operating Income		 89 85 104 98 81 32 88 35 12 -0.69 -3.91
Total Gross Profit		 271 215 199 178 148 94 155 83 51 11 1.41
Total Revenue		 2,035 1,387 1,144 774 687 561 520 356 306 33 10
Operating Revenue		 2,035 1,387 1,144 774 687 561 520 356 282 33 10
Total Cost of Revenue		 1,763 1,172 945 596 539 466 365 273 255 22 9.08
Operating Cost of Revenue		 1,763 1,172 945 596 539 468 361 273 255 22 9.08
Total Operating Expenses		 182 130 95 80 67 62 66 48 39 12 5.32
Selling, General & Admin Expense		 154 113 78 62 49 41 43 26 21 11 5.29
Depreciation Expense		 28 18 18 18 18 18 19 19 18 0.33 0.03
Total Other Income / (Expense), net		 -8.53 5.23 -18 -20 98 -6.58 -5.81 15 7.15 -0.49 -0.63
Interest Expense		 33 16 7.92 5.39 9.50 4.73 0.56 0.08 0.06 1.33 0.68
Interest & Investment Income		 19 20 7.60 -0.54 106 -4.88 -6.87 14 5.25 - -
Other Income / (Expense), net		 5.61 1.54 -17 -14 1.08 3.03 1.62 1.05 1.96 0.84 0.05
Income Tax Expense		 31 32 41 32 56 8.17 22 3.89 8.82 0.16 0.02
Net Income / (Loss) Attributable to Noncontrolling Interest		 6.78 -2.87 0.57 -23 84 3.56 49 20 -1.43 0.45 -
Basic Earnings per Share		 $0.91 $1.30 $1.00 $1.57 $1.03 $0.41 $0.33 $1.01 $0.46 ($0.37) ($0.12)
Weighted Average Basic Shares Outstanding		 56.25M 55.42M 57.44M 55.96M 54.59M 52.80M 32.89M 25.53M 24.67M 4.89M 49.13M
Diluted Earnings per Share		 $0.90 $1.29 $0.99 $1.52 $1.01 $0.39 $0.29 $0.90 $0.41 ($0.37) ($0.12)
Weighted Average Diluted Shares Outstanding		 56.25M 55.42M 57.44M 55.96M 54.59M 52.80M 37.91M 28.66M 27.97M 4.89M 49.13M
Weighted Average Basic & Diluted Shares Outstanding		 56.25M 55.42M 57.44M 55.96M 54.59M 52.80M 32.80M 6.95M 5.21M 4.89M 36.66M

Quarterly Income Statements for Astrana Health

This table shows Astrana Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 16 19 15 22 13 13 -3.73 23
Consolidated Net Income / (Loss)		 19 22 17 28 17 12 -0.88 24
Net Income / (Loss) Continuing Operations		 19 22 17 28 17 12 -0.88 24
Total Pre-Tax Income 		27 32 24 38 31 19 10 41
Total Operating Income		 28 30 30 39 27 22 13 50
Total Gross Profit		 73 73 74 73 55 48 41 76
Total Revenue		 479 486 404 348 348 337 294 317
Operating Revenue		 479 486 404 348 348 337 294 317
Total Cost of Revenue		 405 413 330 275 293 289 253 241
Operating Cost of Revenue		 405 413 330 275 293 289 253 241
Total Operating Expenses		 45 43 44 34 28 25 29 26
Selling, General & Admin Expense		 38 36 39 29 24 21 24 21
Depreciation Expense		 7.26 7.44 5.10 4.31 4.25 4.29 4.06 4.75
Total Other Income / (Expense), net		 -1.61 1.83 -6.14 -1.07 4.46 -2.96 -2.13 -8.83
Interest Expense		 8.86 8.59 7.59 3.78 3.63 3.27 2.57 2.42
Interest & Investment Income		 5.13 4.42 4.63 1.18 6.05 5.49 2.51 1.68
Other Income / (Expense), net		 2.11 6.00 -3.18 1.53 2.04 -5.19 -2.07 -8.08
Income Tax Expense		 7.83 10 7.14 10 14 6.92 11 17
Net Income / (Loss) Attributable to Noncontrolling Interest		 2.89 2.70 2.03 5.91 4.31 -0.64 2.85 0.71
Basic Earnings per Share		 $0.34 $0.40 $0.31 $0.47 $0.28 $0.28 ($0.10) $0.52
Weighted Average Basic Shares Outstanding		 56.25M 56.21M 56.03M 58.28M 57.56M 57.55M 57.44M 44.95M
Diluted Earnings per Share		 $0.33 $0.40 $0.31 $0.47 $0.28 $0.28 ($0.07) $0.50
Weighted Average Diluted Shares Outstanding		 56.25M 56.21M 56.03M 58.28M 57.56M 57.55M 57.44M 46.15M
Weighted Average Basic & Diluted Shares Outstanding		 56.25M 56.21M 56.03M 58.28M 57.56M 57.55M 57.44M 56.72M

Annual Cash Flow Statements for Astrana Health

This table details how cash moves in and out of Astrana Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 3/31/2015 1/31/2014
Net Change in Cash & Equivalents		 -5.05 6.13 55 39 90 -3.63 -11 64 -4.19 -1.82 0.27
Net Cash From Operating Activities		 52 68 82 70 46 14 25 52 22 -0.27 -1.48
Net Cash From Continuing Operating Activities		 52 68 82 70 46 14 25 52 22 -0.27 -1.48
Net Income / (Loss) Continuing Operations		 50 58 46 46 122 18 60 46 10 -1.35 -4.56
Consolidated Net Income / (Loss)		 50 58 46 46 122 18 60 46 10 -1.35 -4.56
Depreciation Expense		 28 18 18 18 18 18 19 19 18 0.33 0.03
Amortization Expense		 1.83 1.06 0.94 1.08 1.35 0.47 0.00 - - 0.52 0.39
Non-Cash Adjustments To Reconcile Net Income		 37 28 38 31 -100 9.31 -4.18 -6.49 0.99 0.50 2.14
Changes in Operating Assets and Liabilities, net		 -64 -36 -20 -25 4.08 -32 -50 -6.57 -7.21 -0.28 0.52
Net Cash From Investing Activities		 -192 -66 -7.11 17 95 -181 -25 27 -8.96 -3.20 -0.27
Net Cash From Continuing Investing Activities		 -192 -66 -7.11 17 95 -181 -25 27 -8.96 -3.20 -0.27
Purchase of Property, Plant & Equipment		 -8.03 -29 -23 -19 -1.16 -1.04 -1.17 -2.08 -3.31 -0.04 -0.02
Acquisitions		 -152 -6.84 -16 -16 -21 -53 -17 0.00 -2.44 -3.36 -0.25
Purchase of Investments		 -6.52 -6.15 -1.85 -28 -1.94 -127 -7.91 -10 -5.21 - -
Sale and/or Maturity of Investments		 0.12 0.49 32 68 67 0.24 0.61 1.44 2.00 0.44 -
Other Investing Activities, net		 -26 -24 1.96 5.93 0.00 0.00 - 0.23 0.00 -0.24 -
Net Cash From Financing Activities		 135 3.42 -20 -48 -52 163 -11 -15 -17 1.66 2.03
Net Cash From Continuing Financing Activities		 135 3.42 -20 -48 -52 163 -11 -15 -17 1.66 2.03
Repayment of Debt		 -19 -205 -4.43 -239 -9.61 -55 -0.59 -9.10 -2.26 -1.47 -1.50
Repurchase of Common Equity		 -0.94 -14 -9.25 -6.47 -0.54 -13 -5.05 -3.18 -0.52 - -
Payment of Dividends		 -3.93 -62 -19 -33 -52 -62 -18 -10 -26 -0.60 -0.24
Issuance of Debt		 172 285 3.60 181 0.00 290 8.00 5.00 0.00 3.00 3.03
Issuance of Common Equity		 0.27 0.00 0.00 40 0.00 0.00 0.20 2.16 11 0.73 0.73
Other Financing Activities, net		 -13 0.52 8.63 9.06 11 3.12 4.00 0.59 0.26 -0.00 0.00
Cash Interest Paid		 30 14 6.67 4.16 8.51 4.26 0.46 0.05 0.06 0.77 0.25
Cash Income Taxes Paid		 44 57 47 37 62 20 24 24 29 0.03 0.02

Quarterly Cash Flow Statements for Astrana Health

This table details how cash moves in and out of Astrana Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2024 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 41 -20 20 -13 104 -50
Net Cash From Operating Activities		 5.98 15 26 7.72 85 -36
Net Cash From Continuing Operating Activities		 5.98 15 26 7.72 85 -36
Net Income / (Loss) Continuing Operations		 17 28 17 12 -0.88 24
Consolidated Net Income / (Loss)		 17 28 17 12 -0.88 24
Depreciation Expense		 5.10 4.31 4.25 4.29 4.06 4.76
Amortization Expense		 0.46 0.24 0.24 0.24 0.24 0.23
Non-Cash Adjustments To Reconcile Net Income		 4.09 5.98 4.46 8.73 8.93 12
Changes in Operating Assets and Liabilities, net		 -21 -23 -0.63 -18 73 -76
Net Cash From Investing Activities		 -71 -35 -5.19 -14 13 -8.09
Net Cash From Continuing Investing Activities		 -71 -35 -5.19 -14 13 -8.09
Purchase of Property, Plant & Equipment		 -0.37 -4.11 -11 -6.03 -0.89 -3.21
Acquisitions		 -51 -5.02 0.35 -0.33 -11 -4.76
Purchase of Investments		 -20 -25 -3.02 -1.00 -0.10 -
Sale and/or Maturity of Investments		 0.01 0.06 0.00 2.14 25 -0.02
Other Investing Activities, net		 0.00 -0.70 8.82 -8.82 -0.32 -0.10
Net Cash From Financing Activities		 106 -0.51 -0.96 -7.10 5.87 -6.25
Net Cash From Continuing Financing Activities		 106 -0.51 -0.96 -7.10 5.87 -6.25
Repayment of Debt		 -3.68 -0.35 -0.31 -0.31 -0.30 -3.65
Repurchase of Common Equity		 0.00 -0.15 - -9.54 0.40 -0.17
Payment of Dividends		 0.03 -1.42 -0.72 -0.12 -6.03 -0.09
Issuance of Debt		 110 1.42 0.12 1.62 1.61 0.75
Other Financing Activities, net		 0.00 - -0.05 1.25 10 -3.09
Cash Interest Paid		 6.43 3.41 3.27 2.99 2.29 2.16
Cash Income Taxes Paid		 0.19 - - 0.00 5.50 20

Annual Balance Sheets for Astrana Health

This table presents Astrana Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 3/31/2015 3/31/2014
Total Assets		 1,355 933 966 867 817 729 513 491 350 15 9.48
Total Current Assets		 638 462 428 404 339 329 173 144 81 9.85 8.43
Cash & Equivalents		 288 294 288 233 193 103 107 100 55 5.01 6.83
Short-Term Investments		 2.38 2.50 5.57 53 68 117 1.13 1.14 1.05 - -
Accounts Receivable		 305 137 117 90 61 76 57 20 22 4.05 1.53
Prepaid Expenses		 23 17 15 19 17 10 7.39 5.14 1.85 0.79 0.04
Current Deferred & Refundable Income Taxes		 19 11 0.00 - - - - - - - -
Plant, Property, & Equipment, net		 14 7.17 109 53 30 12 13 14 10 0.58 0.09
Total Noncurrent Assets		 702 465 430 410 449 388 327 333 258 4.56 0.96
Long-Term Investments		 48 32 43 43 80 29 35 22 35 - -
Noncurrent Note & Lease Receivables		 51 26 0.00 0.57 4.63 0.00 18 15 5.20 - -
Goodwill		 419 279 269 246 239 239 186 190 103 2.17 0.49
Intangible Assets		 118 72 77 83 87 103 87 104 108 1.38 0.06
Noncurrent Deferred & Refundable Income Taxes		 16 16 16 16 - - - - - - -
Other Noncurrent Operating Assets		 49 40 25 21 38 17 1.95 2.38 6.94 0.75 0.04
Total Liabilities & Shareholders' Equity		 1,355 933 966 867 817 729 513 491 350 15 9.48
Total Liabilities		 841 523 408 357 372 368 106 154 100 16 11
Total Current Liabilities		 366 219 149 115 115 105 72 110 51 5.97 2.44
Short-Term Debt		 9.38 20 0.62 0.78 11 9.50 0.04 0.61 0.10 1.04 -
Accounts Payable		 114 68 58 54 46 29 27 20 9.13 3.34 1.45
Dividends Payable		 0.64 0.64 0.66 0.56 0.49 0.27 0.00 - - - -
Other Current Liabilities		 241 131 85 59 54 62 34 85 39 1.59 1.00
Total Noncurrent Liabilities		 475 304 259 242 257 262 34 45 49 10 8.66
Long-Term Debt		 425 259 203 183 230 232 0.00 - - 7.69 6.31
Noncurrent Deferred & Payable Income Tax Liabilities		 4.56 4.07 14 30 11 18 20 25 47 0.17 0.00
Other Noncurrent Operating Liabilities		 45 41 41 29 16 12 1.19 19 2.00 2.14 2.35
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 -203 -206 14 57 114 169 225 172 163 0.00 -
Total Equity & Noncontrolling Interests		 717 617 544 454 331 192 182 164 88 -0.99 -1.62
Total Preferred & Common Equity		 713 614 543 448 331 192 181 160 87 -2.82 -1.22
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 713 614 543 448 331 192 181 160 87 -2.82 -1.22
Common Stock		 426 371 360 311 261 160 163 158 88 17 15
Retained Earnings		 286 243 182 137 70 32 18 1.73 -0.77 -19 -16
Noncontrolling Interest		 4.01 2.43 1.75 5.94 0.09 0.79 1.00 4.24 0.38 1.83 -0.41

Quarterly Balance Sheets for Astrana Health

This table presents Astrana Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,285 1,252 1,226 1,073 1,027 999 943
Total Current Assets		 597 570 539 476 465 455 444
Cash & Equivalents		 348 325 335 274 294 275 184
Short-Term Investments		 2.35 2.38 2.49 3.02 3.79 4.11 33
Accounts Receivable		 210 203 184 184 151 153 202
Prepaid Expenses		 21 17 17 14 15 22 12
Current Deferred & Refundable Income Taxes		 16 22 0.00 - - 0.00 12
Plant, Property, & Equipment, net		 12 10 7.99 129 124 113 104
Total Noncurrent Assets		 676 672 679 468 438 431 396
Long-Term Investments		 44 42 42 47 49 44 40
Noncurrent Note & Lease Receivables		 55 49 47 25 - - 2.64
Goodwill		 410 410 410 276 274 269 257
Intangible Assets		 109 116 120 74 74 78 73
Noncurrent Deferred & Refundable Income Taxes		 16 16 16 16 16 16 -
Other Noncurrent Operating Assets		 43 39 44 30 25 24 22
Total Liabilities & Shareholders' Equity		 1,285 1,252 1,226 1,073 1,027 999 943
Total Liabilities		 778 774 774 458 444 434 390
Total Current Liabilities		 313 310 355 203 186 173 156
Short-Term Debt		 15 17 21 2.99 2.63 0.62 3.16
Accounts Payable		 101 103 154 59 59 58 54
Dividends Payable		 0.64 0.64 0.64 0.64 0.64 0.66 0.56
Other Current Liabilities		 196 189 174 110 104 102 99
Total Noncurrent Liabilities		 465 464 419 255 258 260 234
Long-Term Debt		 423 425 368 206 205 205 199
Noncurrent Deferred & Payable Income Tax Liabilities		 2.86 3.25 3.76 12 12 14 4.70
Other Noncurrent Operating Liabilities		 39 36 45 36 39 40 30
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 -203 -204 -206 18 14 14 40
Total Equity & Noncontrolling Interests		 710 683 658 598 570 551 514
Total Preferred & Common Equity		 705 679 653 594 566 548 510
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 705 679 653 594 566 548 510
Common Stock		 411 402 396 363 357 353 315
Retained Earnings		 293 277 258 231 209 196 195
Noncontrolling Interest		 5.00 4.13 4.49 4.00 3.74 2.71 3.07

Annual Metrics And Ratios for Astrana Health

This table displays calculated financial ratios and metrics derived from Astrana Health's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 3/31/2015 1/31/2014
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 46.72% 21.19% 47.84% 12.62% 22.58% 7.83% 45.90% 16.48% 827.36% 214.66% 34.83%
EBITDA Growth		 18.82% -0.43% 3.07% 0.99% 86.85% -50.43% 97.87% 74.02% 3,080.20% 129.06% 52.19%
EBIT Growth		 10.22% -0.90% 3.89% 2.58% 130.13% -60.63% 148.83% 32.62% 19,084.99% 103.68% 51.56%
NOPAT Growth		 1.32% -1.05% -5.32% 5.58% 148.41% -65.62% 99.09% 421.06% 1,379.27% 82.24% -88.11%
Net Income Growth		 -13.69% 26.47% -0.68% -62.28% 590.79% -70.68% 31.52% 357.34% 843.33% 70.43% 48.80%
EPS Growth		 -30.23% 30.30% -34.87% 50.50% 158.97% 34.48% -67.78% 119.51% 421.62% -208.33% 55.56%
Operating Cash Flow Growth		 -23.49% -16.93% 16.77% 52.36% 237.62% -46.37% -50.81% 136.54% 16,318.40% 81.61% -2,650.56%
Free Cash Flow Firm Growth		 -261.49% 1,119.33% -127.22% -32.14% 216.38% -249.46% -110.11% 152.04% -5,571.54% -6,701.33% 90.63%
Invested Capital Growth		 68.92% -15.36% 18.56% 4.31% -2.45% 27.79% 40.75% -38.42% 12,784.07% 197.12% -2,160.19%
Revenue Q/Q Growth		 0.00% 4.43% 9.48% 2.42% -0.29% 14.77% 2.77% -33.70% 631.54% 27.29% 8.25%
EBITDA Q/Q Growth		 0.00% -8.92% 42.07% -31.27% 16.09% 19.56% 7.04% -38.61% 1,396.82% 352.89% -29.17%
EBIT Q/Q Growth		 0.00% -11.54% 56.84% -35.68% 21.27% 31.01% 8.93% -37.38% 1,058.05% -93.55% -22.94%
NOPAT Q/Q Growth		 0.00% -6.12% 30.81% -26.57% 19.67% 24.94% -9.62% -4.87% 282.58% 50.51% -20.94%
Net Income Q/Q Growth		 0.00% 1.38% 89.99% -43.33% 12.90% 3.89% -27.49% 17.53% 347.88% 34.04% -13.70%
EPS Q/Q Growth		 0.00% 34.38% -21.43% -3.80% 6.32% 254.55% -65.88% -48.86% 147.13% 17.78% -9.09%
Operating Cash Flow Q/Q Growth		 0.00% -49.03% 647.48% -12.00% -11.82% 267.94% -46.19% -13.70% 896.00% -1,054.20% -39.80%
Free Cash Flow Firm Q/Q Growth		 0.00% 114.81% 90.25% -26.13% -14.58% -7.00% 92.23% 494.16% -27,207.32% -331.51% 96.30%
Invested Capital Q/Q Growth		 0.00% -27.90% -14.45% 7.13% 9.41% 2.84% 0.64% 9,253.81% 5,565.79% 171.63% -2,850.14%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 13.34% 15.50% 17.43% 22.97% 21.53% 16.80% 29.79% 23.26% 39.53% 33.11% 13.43%
EBITDA Margin		 6.13% 7.57% 9.21% 13.22% 14.74% 9.67% 21.03% 15.51% 20.76% 3.03% -32.78%
Operating Margin		 4.39% 6.10% 9.11% 12.69% 11.72% 5.78% 17.01% 9.86% 7.64% -2.10% -37.29%
EBIT Margin		 4.67% 6.21% 7.60% 10.81% 11.87% 6.32% 17.32% 10.16% 8.92% 0.43% -36.82%
Profit (Net Income) Margin		 2.45% 4.17% 4.00% 5.95% 17.77% 3.15% 11.59% 12.86% 6.55% -4.09% -43.48%
Tax Burden Percent		 61.78% 64.39% 52.81% 59.24% 68.42% 68.39% 72.94% 92.18% 152.33% 113.83% 100.43%
Interest Burden Percent		 85.11% 104.28% 99.63% 92.91% 218.71% 72.89% 91.75% 137.36% 276.10% -832.50% 117.59%
Effective Tax Rate		 38.22% 35.61% 47.19% 40.76% 31.58% 31.61% 27.06% 7.82% 46.81% 0.00% 0.00%
Return on Invested Capital (ROIC)		 11.36% 13.82% 13.99% 16.49% 15.76% 7.03% 27.24% 12.55% 7.67% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -11.13% 10.11% 20.60% 26.15% -109.33% 13.60% 30.38% 1.34% -1.05% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -0.56% -1.89% -5.44% -6.85% 14.53% -2.43% -11.01% -0.54% 0.37% 0.00% 0.00%
Return on Equity (ROE)		 10.80% 11.94% 8.56% 9.64% 30.29% 4.60% 16.22% 12.01% 8.03% 103.16% 452.60%
Cash Return on Invested Capital (CROIC)		 -39.90% 30.46% -2.99% 12.27% 18.24% -17.37% -6.62% 60.10% -383.23% -222.71% 0.00%
Operating Return on Assets (OROA)		 8.30% 9.07% 9.48% 9.93% 10.55% 5.71% 17.95% 8.61% 14.95% 1.16% -60.76%
Return on Assets (ROA)		 4.36% 6.09% 4.99% 5.47% 15.79% 2.85% 12.01% 10.90% 10.98% -11.01% -71.76%
Return on Common Equity (ROCE)		 15.49% 14.24% 7.93% 7.85% 19.62% 2.23% 7.43% 5.06% 55,787.31% 159.19% 352.72%
Return on Equity Simple (ROE_SIMPLE)		 7.01% 9.42% 8.43% 10.28% 36.90% 9.23% 33.38% 28.65% 11.49% 47.84% 375.19%
Net Operating Profit after Tax (NOPAT)		 55 54 55 58 55 22 65 32 6.22 -0.49 -2.74
NOPAT Margin		 2.71% 3.93% 4.81% 7.51% 8.02% 3.96% 12.41% 9.09% 4.06% -1.47% -26.10%
Net Nonoperating Expense Percent (NNEP)		 22.50% 3.72% -6.61% -9.66% 125.08% -6.57% -3.14% 11.22% 446.82% 67.86% -920.47%
Return On Investment Capital (ROIC_SIMPLE)		 4.79% 6.09% 7.36% - - - - - - - -
Cost of Revenue to Revenue		 86.66% 84.50% 82.57% 77.03% 78.47% 83.20% 70.21% 76.74% 166.55% 66.89% 86.57%
SG&A Expenses to Revenue		 7.57% 8.12% 6.79% 8.02% 7.15% 7.40% 8.34% 7.37% 45.38% 34.20% 50.42%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 8.95% 9.40% 8.32% 10.28% 9.82% 11.02% 12.78% 13.40% 52.21% 35.21% 50.72%
Earnings before Interest and Taxes (EBIT)		 95 86 87 84 82 35 90 36 27 0.14 -3.86
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 125 105 105 102 101 54 109 55 32 1.00 -3.44
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 3.01 5.08 4.17 4.30 0.21 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 208.37 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 1.45 1.73 1.45 1.93 0.06 0.10 2.81
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 26.46 68.87 69.46 26.66 1.59 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 3.78% 1.45% 1.44% 3.75% 63.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 2.93 3.21 3.02 3.68 0.57 3.55 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 1.47 2.02 1.61 2.03 0.59 0.26 2.72
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 9.98 20.92 7.64 13.11 2.86 8.73 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 12.39 31.99 9.28 20.02 6.65 61.32 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 18.36 51.15 12.96 22.37 14.59 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 21.90 82.95 32.79 13.98 4.14 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 15.86 0.00 0.00 4.67 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.85 0.68 0.37 0.36 0.54 0.67 0.00 0.00 0.13 -8.82 -3.89
Long-Term Debt to Equity		 0.83 0.63 0.36 0.36 0.52 0.64 0.00 0.00 0.00 -7.77 -3.89
Financial Leverage		 0.05 -0.19 -0.26 -0.26 -0.13 -0.18 -0.36 -0.41 -0.70 -0.97 0.20
Leverage Ratio		 2.47 1.96 1.71 1.76 1.92 1.62 1.35 1.43 72.97 -9.37 -6.31
Compound Leverage Factor		 2.11 2.04 1.71 1.64 4.19 1.18 1.24 1.97 81.30 77.98 -7.42
Debt to Total Capital		 45.81% 40.40% 26.75% 26.46% 35.13% 40.10% 0.14% 0.36% 11.40% 112.79% 134.65%
Short-Term Debt to Total Capital		 0.99% 2.83% 0.08% 0.11% 1.59% 1.58% 0.01% 0.18% 0.04% 13.41% 0.00%
Long-Term Debt to Total Capital		 44.82% 37.57% 26.67% 26.34% 33.55% 38.52% 0.13% 0.18% 0.00% 99.38% 134.65%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 233.70% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -20.93% -29.52% 2.10% 9.00% 16.66% 28.12% 55.53% 52.25% 230.16% 23.61% -8.71%
Common Equity to Total Capital		 75.11% 89.12% 71.15% 64.55% 48.21% 31.78% 44.34% 47.39% 69.61% -36.41% -25.94%
Debt to EBITDA		 3.49 2.65 1.94 1.80 2.38 4.46 0.01 0.02 0.00 8.74 -1.84
Net Debt to EBITDA		 0.77 -0.48 -1.25 -1.42 -0.99 -0.14 -1.31 -2.53 -0.27 3.72 0.16
Long-Term Debt to EBITDA		 3.41 2.47 1.93 1.79 2.27 4.28 0.00 0.01 0.00 7.70 -1.84
Debt to NOPAT		 7.87 5.11 3.71 3.16 4.38 10.90 0.01 0.04 0.03 -17.96 -2.30
Net Debt to NOPAT		 1.73 -0.92 -2.40 -2.50 -1.82 -0.34 -2.21 -4.31 -11.02 -7.64 0.20
Long-Term Debt to NOPAT		 7.70 4.75 3.69 3.15 4.18 10.47 0.01 0.02 0.00 -15.83 -2.30
Altman Z-Score		 0.00 0.00 0.00 0.00 3.22 2.95 6.12 3.73 1.21 0.86 -0.30
Noncontrolling Interest Sharing Ratio		 -43.46% -19.34% 7.34% 18.50% 35.21% 51.53% 54.17% 57.88% 1,815.55% -54.31% 22.07%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.75 2.11 2.88 3.53 2.94 3.12 2.40 1.32 5.25 1.65 3.45
Quick Ratio		 1.63 1.98 2.78 3.31 2.80 3.02 2.30 1.10 3.33 1.52 3.42
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -194 120 -12 43 64 -55 -16 155 -298 -5.48 -0.08
Operating Cash Flow to CapEx		 649.96% 239.15% 358.01% 365.89% 4,143.90% 1,312.19% 2,179.15% 2,486.31% 1,325.58% -610.91% -6,446.32%
Free Cash Flow to Firm to Interest Expense		 -5.86 7.46 -1.49 8.02 6.71 -11.58 -27.95 1,946.72 -5,023.72 -4.13 -0.12
Operating Cash Flow to Interest Expense		 1.58 4.24 10.37 13.04 4.86 2.89 45.45 650.45 711.61 -0.21 -2.18
Operating Cash Flow Less CapEx to Interest Expense		 1.33 2.47 7.47 9.48 4.74 2.67 43.36 624.29 604.25 -0.24 -2.21
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.78 1.46 1.25 0.92 0.89 0.90 1.04 0.85 4.23 2.70 1.65
Accounts Receivable Turnover		 9.19 10.93 11.10 10.30 10.06 8.40 13.40 16.81 46.49 11.83 6.72
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 189.74 23.97 14.15 18.63 32.71 45.12 39.19 29.47 111.70 97.40 128.57
Accounts Payable Turnover		 19.37 18.70 16.85 11.89 14.36 16.68 15.55 18.57 81.69 9.22 7.57
Days Sales Outstanding (DSO)		 39.70 33.39 32.90 35.43 36.29 43.45 27.23 21.71 49.02 30.86 54.32
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 18.84 19.52 21.66 30.70 25.42 21.88 23.47 19.66 51.41 39.59 48.21
Cash Conversion Cycle (CCC)		 20.86 13.87 11.24 4.73 10.87 21.57 3.76 2.05 6.77 -8.73 6.11
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 610 361 427 360 345 354 277 197 319 2.46 -2.53
Invested Capital Turnover		 4.19 3.52 2.91 2.19 1.97 1.78 2.20 1.38 7.54 -905.47 -8.70
Increase / (Decrease) in Invested Capital		 249 -66 67 15 -8.68 77 80 -123 634 4.99 -2.66
Enterprise Value (EV)		 0.00 0.00 0.00 0.00 1,011 1,134 836 725 91 8.72 29
Market Capitalization		 0.00 0.00 0.00 0.00 997 972 753 688 36 3.18 29
Book Value per Share		 $12.67 $10.54 $9.57 $8.07 $6.10 $5.49 $5.30 $26.51 $29.28 ($0.06) ($0.03)
Tangible Book Value per Share		 $3.12 $4.53 $3.47 $2.14 $0.09 ($4.30) ($2.70) ($22.12) ($20.87) ($0.13) ($0.05)
Total Capital		 949 689 763 694 686 603 407 338 501 7.74 4.68
Total Debt		 435 278 204 184 241 242 0.56 1.23 0.29 8.73 6.31
Total Long-Term Debt		 425 259 203 183 230 232 0.52 0.62 0.00 7.69 6.31
Net Debt		 96 -50 -132 -145 -100 -7.45 -143 -140 -100 3.72 -0.54
Capital Expenditures (CapEx)		 8.03 29 23 19 1.11 1.04 1.17 2.08 6.61 0.04 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.57 -34 -13 4.01 -27 13 -7.14 -84 -28 -0.09 -0.87
Debt-free Net Working Capital (DFNWC)		 282 262 280 291 234 233 101 35 61 4.92 5.98
Net Working Capital (NWC)		 273 243 280 290 224 224 101 35 61 3.89 5.98
Net Nonoperating Expense (NNE)		 5.27 -3.36 9.32 12 -67 4.50 4.23 -13 -0.72 0.86 1.82
Net Nonoperating Obligations (NNO)		 96 -49 -132 -151 -100 -7.18 -130 -140 -100 3.45 -0.91
Total Depreciation and Amortization (D&A)		 30 19 18 19 20 19 19 19 36 0.86 0.42
Debt-free, Cash-free Net Working Capital to Revenue		 -0.42% -2.45% -1.18% 0.52% -3.88% 2.38% -1.37% -23.50% -21.70% -0.27% -8.29%
Debt-free Net Working Capital to Revenue		 13.87% 18.92% 24.48% 37.54% 34.12% 41.59% 19.40% 9.87% 38.69% 14.93% 57.06%
Net Working Capital to Revenue		 13.41% 17.51% 24.43% 37.44% 32.54% 39.89% 19.40% 9.70% 23.89% 11.78% 57.06%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.91 $1.30 $0.00 $1.69 $1.04 $0.41 $0.33 $0.00 ($1.33) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 56.25M 55.42M 0.00 55.96M 36.53M 34.71M 32.89M 0.00 30.42M 0.00 0.00
Adjusted Diluted Earnings per Share		 $0.90 $1.29 $0.00 $1.63 $1.01 $0.39 $0.29 $0.00 ($1.38) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 56.25M 55.42M 0.00 55.96M 37.45M 36.40M 37.91M 0.00 5.75M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($1.79) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 56.25M 55.42M 0.00 55.96M 54.59M 52.80M 35.80M 0.00 10.43M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 55 54 55 58 55 24 67 35 6.39 -0.49 -2.74
Normalized NOPAT Margin		 2.71% 3.93% 4.81% 7.51% 8.02% 4.20% 12.94% 9.72% 4.18% -1.47% -26.10%
Pre Tax Income Margin		 3.97% 6.48% 7.57% 10.05% 25.97% 4.61% 15.89% 13.95% 12.31% -3.59% -43.30%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 2.87 5.35 10.98 15.51 8.59 7.49 160.52 454.15 221.54 0.11 -5.68
NOPAT to Interest Expense		 1.67 3.38 6.95 10.78 5.80 4.68 114.98 406.56 302.86 -0.37 -4.03
EBIT Less CapEx to Interest Expense		 2.63 3.58 8.08 11.95 8.47 7.27 158.44 427.99 335.72 0.07 -5.72
NOPAT Less CapEx to Interest Expense		 1.43 1.61 4.06 7.22 5.68 4.46 112.89 380.39 141.81 -0.40 -4.06
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 7.86% 107.44% 40.75% 70.59% 42.89% 349.06% 29.42% 22.80% 509.69% -44.51% -5.26%
Augmented Payout Ratio		 9.74% 131.85% 60.97% 84.63% 43.33% 424.55% 37.80% 29.73% 520.02% -44.51% -5.26%

Quarterly Metrics And Ratios for Astrana Health

This table displays calculated financial ratios and metrics derived from Astrana Health's official financial filings.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - -
Revenue Growth		 37.49% 39.65% 19.90% 9.83% 29.11% 28.10% 50.80% 39.58%
EBITDA Growth		 -16.29% 29.65% 49.74% -3.90% 58.76% -3.38% 190.32% 2,015.78%
EBIT Growth		 -24.82% 24.06% 56.89% -3.32% 75.67% -3.79% 150.10% 676.82%
NOPAT Growth		 -30.03% 37.36% 47.08% -0.86% 43.84% -12.38% -167.46% -22.04%
Net Income Growth		 -32.15% 25.08% 35.03% 17.06% 55.02% 9.07% 96.08% 543.77%
EPS Growth		 -29.79% 42.86% 10.71% -6.00% 7.69% -6.67% -135.00% -32.43%
Operating Cash Flow Growth		 0.00% 0.00% -22.58% 142.95% 186.02% -67.88% 796.79% -170.01%
Free Cash Flow Firm Growth		 -215.27% -287.15% 116.51% 119.87% 71.22% -96.89% -421.18% -907.55%
Invested Capital Growth		 10.13% 23.57% 3.06% 0.43% 9.00% 15.15% 18.98% 48.47%
Revenue Q/Q Growth		 -1.55% 20.26% 0.00% -0.01% 3.25% 14.63% -7.19% 17.54%
EBITDA Q/Q Growth		 -13.12% 33.82% 0.00% 34.57% 54.55% 46.57% -68.47% 122.32%
EBIT Q/Q Growth		 -15.34% 33.78% 0.00% 39.71% 69.18% 63.42% -74.97% 153.84%
NOPAT Q/Q Growth		 -2.37% -2.65% 0.00% 91.66% 4.24% 1,454.89% -103.66% 178.10%
Net Income Q/Q Growth		 -13.19% 29.68% 0.00% 60.01% 39.99% 1,514.27% -103.70% 111.91%
EPS Q/Q Growth		 -17.50% 29.03% 0.00% 67.86% 0.00% 500.00% -114.00% 92.31%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% -40.30% 234.22% -90.91% 336.80% -497.63%
Free Cash Flow Firm Q/Q Growth		 63.73% -1,243.46% 0.00% 221.82% 51.25% 35.44% 48.17% -76.44%
Invested Capital Q/Q Growth		 0.09% 18.93% 0.00% 12.30% -0.80% 5.02% -14.15% 21.88%
Profitability Metrics		 - - - - - - - -
Gross Margin		 15.35% 15.11% 18.29% 20.91% 15.89% 14.19% 13.97% 24.05%
EBITDA Margin		 7.90% 8.95% 8.04% 12.97% 9.64% 6.44% 5.04% 14.82%
Operating Margin		 5.94% 6.18% 7.45% 11.23% 7.76% 6.63% 4.28% 15.80%
EBIT Margin		 6.38% 7.42% 6.67% 11.67% 8.35% 5.10% 3.57% 13.25%
Profit (Net Income) Margin		 3.97% 4.50% 4.17% 8.03% 5.02% 3.70% -0.30% 7.54%
Tax Burden Percent		 70.79% 68.55% 70.25% 73.58% 55.51% 64.34% -8.44% 57.91%
Interest Burden Percent		 87.80% 88.43% 89.03% 93.59% 108.32% 112.94% 99.43% 98.22%
Effective Tax Rate		 29.21% 31.45% 29.75% 26.42% 44.49% 35.66% 108.44% 42.09%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 21.93% 13.06% 12.37% -1.05% 22.90%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 22.86% 11.11% 13.86% -1.18% 26.99%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% -3.30% -2.54% -3.24% 0.31% -6.22%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 18.63% 10.52% 9.13% -0.74% 16.68%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 11.17% 4.91% -1.35% -3.37% -28.93%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 15.36% 10.95% 6.50% 4.46% 15.26%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 10.58% 6.58% 4.72% -0.37% 8.68%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 17.60% 9.92% 8.51% -0.69% 14.55%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 9.61% 9.36% 8.53% 0.00% 4.72%
Net Operating Profit after Tax (NOPAT)		 20 21 21 29 15 14 -1.06 29
NOPAT Margin		 4.20% 4.24% 5.24% 8.26% 4.31% 4.27% -0.36% 9.15%
Net Nonoperating Expense Percent (NNEP)		 -3.28% 3.89% -8.28% -0.93% 1.95% -1.49% 0.13% -4.09%
Cost of Revenue to Revenue		 84.65% 84.89% 81.71% 79.09% 84.11% 85.81% 86.03% 75.95%
SG&A Expenses to Revenue		 7.90% 7.39% 9.58% 8.45% 6.91% 6.28% 8.31% 6.75%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 9.41% 8.92% 10.84% 9.68% 8.13% 7.55% 9.69% 8.25%
Earnings before Interest and Taxes (EBIT)		 31 36 27 41 29 17 11 42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 38 44 33 45 34 22 15 47
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 3.13 3.53
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 8.64 10.02
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 1.49 1.72
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 37.62 31.18
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.66% 3.21%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 3.70 3.58
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 1.39 1.71
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 15.03 24.10
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 18.23 32.26
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 28.78 42.48
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 19.30 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.86 0.92 0.86 0.34 0.36 0.37 0.37 0.37
Long-Term Debt to Equity		 0.83 0.89 0.82 0.34 0.35 0.36 0.36 0.36
Financial Leverage		 -0.06 -0.06 -0.10 -0.14 -0.23 -0.23 -0.26 -0.23
Leverage Ratio		 2.10 2.15 2.19 1.73 1.78 1.74 1.71 1.67
Compound Leverage Factor		 1.84 1.90 1.95 1.61 1.93 1.97 1.71 1.64
Debt to Total Capital		 46.35% 48.01% 46.31% 25.36% 26.35% 26.78% 26.75% 26.77%
Short-Term Debt to Total Capital		 1.59% 1.85% 2.46% 0.36% 0.33% 0.08% 0.08% 0.42%
Long-Term Debt to Total Capital		 44.76% 46.16% 43.85% 25.00% 26.02% 26.69% 26.67% 26.36%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -20.90% -21.74% -23.86% 2.66% 2.22% 2.20% 2.10% 5.68%
Common Equity to Total Capital		 74.54% 73.73% 77.55% 71.98% 71.43% 71.02% 71.15% 67.55%
Debt to EBITDA		 0.00 0.00 0.00 1.82 1.78 1.98 1.94 2.73
Net Debt to EBITDA		 0.00 0.00 0.00 -1.00 -1.18 -1.11 -1.24 -0.74
Long-Term Debt to EBITDA		 0.00 0.00 0.00 1.79 1.76 1.97 1.93 2.68
Debt to NOPAT		 0.00 0.00 0.00 3.60 3.61 3.86 3.71 4.81
Net Debt to NOPAT		 0.00 0.00 0.00 -1.98 -2.38 -2.17 -2.38 -1.30
Long-Term Debt to NOPAT		 0.00 0.00 0.00 3.55 3.56 3.85 3.69 4.73
Altman Z-Score		 0.00 0.00 0.00 0.00 0.00 0.00 4.33 4.68
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 5.54% 5.72% 6.81% 7.34% 12.79%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 1.91 1.84 1.52 2.35 2.50 2.62 2.88 2.84
Quick Ratio		 1.79 1.71 1.47 2.28 2.42 2.50 2.78 2.69
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -31 -85 7.40 27 -22 -45 -69 -134
Operating Cash Flow to CapEx		 0.00% 0.00% 1,619.78% 375.27% 227.53% 128.09% 9,586.79% -1,117.79%
Free Cash Flow to Firm to Interest Expense		 -3.46 -9.85 0.98 7.04 -6.01 -13.71 -26.99 -55.29
Operating Cash Flow to Interest Expense		 0.00 0.00 0.79 4.08 7.10 2.36 33.04 -14.81
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.74 2.99 3.98 0.52 32.69 -16.14
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 1.32 1.31 1.27 1.25 1.15
Accounts Receivable Turnover		 0.00 0.00 0.00 6.87 8.29 8.18 11.10 7.45
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 11.41 12.29 13.26 14.15 13.62
Accounts Payable Turnover		 0.00 0.00 0.00 19.61 17.29 17.93 16.85 14.37
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 53.15 44.05 44.61 32.90 48.99
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 18.61 21.11 20.35 21.66 25.41
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 34.54 22.94 24.26 11.24 23.58
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 552 551 464 501 446 450 428 499
Invested Capital Turnover		 0.00 0.00 0.00 2.66 3.03 2.90 2.90 2.50
Increase / (Decrease) in Invested Capital		 51 105 14 2.15 37 59 68 163
Enterprise Value (EV)		 0.00 0.00 0.00 0.00 0.00 0.00 1,585 1,788
Market Capitalization		 0.00 0.00 0.00 0.00 0.00 0.00 1,700 1,800
Book Value per Share		 $12.53 $12.12 $11.79 $10.32 $9.84 $9.55 $9.57 $9.04
Tangible Book Value per Share		 $3.31 $2.73 $2.23 $4.24 $3.78 $3.50 $3.47 $3.18
Total Capital		 945 921 843 825 792 772 763 756
Total Debt		 438 442 390 209 209 207 204 202
Total Long-Term Debt		 423 425 369 206 206 206 203 199
Net Debt		 44 72 11 -115 -138 -116 -131 -55
Capital Expenditures (CapEx)		 0.00 0.00 0.37 4.11 11 6.03 0.89 3.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -51 -50 -133 -0.70 -16 3.33 -13 73
Debt-free Net Working Capital (DFNWC)		 299 278 204 276 282 282 280 291
Net Working Capital (NWC)		 284 261 184 273 279 281 280 287
Net Nonoperating Expense (NNE)		 1.14 -1.26 4.31 0.79 -2.48 1.91 -0.18 5.11
Net Nonoperating Obligations (NNO)		 45 73 11 -114 -137 -115 -130 -54
Total Depreciation and Amortization (D&A)		 7.26 7.44 5.55 4.54 4.49 4.53 4.30 4.98
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -0.05% -1.25% 0.27% -1.18% 7.01%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 20.81% 21.74% 23.15% 24.48% 27.81%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 20.58% 21.54% 23.10% 24.43% 27.50%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.34 $0.40 $0.31 $0.47 $0.28 $0.00 ($0.10) $0.58
Adjusted Weighted Average Basic Shares Outstanding		 56.25M 56.21M 56.03M 46.55M 57.56M 0.00 57.44M 56.72M
Adjusted Diluted Earnings per Share		 $0.33 $0.40 $0.31 $0.47 $0.28 $0.00 ($0.07) $0.56
Adjusted Weighted Average Diluted Shares Outstanding		 56.25M 56.21M 56.03M 46.92M 57.56M 0.00 57.44M 56.72M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 56.25M 56.21M 56.03M 58.28M 57.56M 0.00 57.44M 56.72M
Normalized Net Operating Profit after Tax (NOPAT)		 20 21 21 29 15 14 8.81 29
Normalized NOPAT Margin		 4.20% 4.24% 5.24% 8.26% 4.31% 4.27% 2.99% 9.15%
Pre Tax Income Margin		 5.60% 6.56% 5.94% 10.92% 9.04% 5.76% 3.55% 13.02%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 3.45 4.20 3.55 10.75 8.00 5.26 4.09 17.35
NOPAT to Interest Expense		 2.27 2.40 2.79 7.61 4.13 4.40 -0.41 11.98
EBIT Less CapEx to Interest Expense		 0.00 0.00 3.51 9.66 4.88 3.41 3.75 16.02
NOPAT Less CapEx to Interest Expense		 0.00 0.00 2.74 6.52 1.01 2.56 -0.76 10.65
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 14.54% 13.14% 37.67% 40.75% 58.28%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 30.82% 30.71% 77.34% 60.97% 101.37%

Frequently Asked Questions About Astrana Health's Financials

When does Astrana Health's fiscal year end?

According to the most recent income statement we have on file, Astrana Health's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Astrana Health's net income changed over the last 10 years?

Astrana Health's net income appears to be on an upward trend, with a most recent value of $49.93 million in 2024, falling from -$4.56 million in 2014. The previous period was $57.85 million in 2023. View Astrana Health's forecast to see where analysts expect Astrana Health to go next.

What is Astrana Health's operating income?
Astrana Health's total operating income in 2024 was $89.35 million, based on the following breakdown:
  • Total Gross Profit: $271.39 million
  • Total Operating Expenses: $182.04 million
How has Astrana Health revenue changed over the last 10 years?

Over the last 10 years, Astrana Health's total revenue changed from $10.48 million in 2014 to $2.03 billion in 2024, a change of 19,305.6%.

How much debt does Astrana Health have?

Astrana Health's total liabilities were at $840.73 million at the end of 2024, a 60.9% increase from 2023, and a 7,469.7% increase since 2014.

How much cash does Astrana Health have?

In the past 10 years, Astrana Health's cash and equivalents has ranged from $5.01 million in 2015 to $293.81 million in 2023, and is currently $288.46 million as of their latest financial filing in 2024.

How has Astrana Health's book value per share changed over the last 10 years?

Over the last 10 years, Astrana Health's book value per share changed from -0.03 in 2014 to 12.67 in 2024, a change of -39,693.8%.


Related Companies

This page (NASDAQ:ASTH) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored